Claims for Patent: 11,191,739

Summary for Patent: 11,191,739

Title:	Bupropion as a modulator of drug activity
Abstract:	Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Inventor(s):	Tabuteau; Herriot (New York, NY)
Assignee:	ANTECIP BIOVENTURES II LLC (New York, NY)
Application Number:	17/192,192
Patent Claims:	1. A dosage form comprising: about 105 mg of bupropion hydrochloride and about 45 mg of dextromethorphan hydrobromide; or an amount of a bupropion in the free base form or a salt form and an amount of a dextromethorphan in the free base form or a salt form that provides about the same AUC.sub.0-12 of bupropion and about the same AUC.sub.0-12 of dextromethorphan in a human being as administering: about 105 mg of bupropion hydrochloride and about 45 mg of dextromethorphan hydrobromide to the human being. 2. The dosage form of claim 1, comprising about 105 mg of bupropion hydrochloride and about 45 mg of dextromethorphan hydrobromide. 3. The dosage form of claim 1, wherein the dextromethorphan is formulated for immediate release. 4. The dosage form of claim 1, wherein the bupropion is formulated for sustained release. 5. A method of systemically delivering bupropion and dextromethorphan, comprising administering the dosage form of claim 1 to a human being. 6. The method of claim 5, wherein the dosage form is administered orally. 7. The method of claim 5, wherein the dosage form is administered once daily. 8. The method of claim 5, wherein the dosage form is administered twice daily. 9. The method of claim 5, wherein the dosage form is administered for at least 8 consecutive days. 10. The method of claim 5, wherein the dosage form is administered for at least 14 consecutive days. 11. The method of claim 5, wherein the dosage form is administered for at least 30 consecutive days. 12. A dosage form comprising: about 210 mg of bupropion hydrochloride and about 90 mg of dextromethorphan hydrobromide; or an amount of a bupropion in the free base form or a salt form and an amount of a dextromethorphan in the free base form or a salt form that provides about the same AUC.sub.0-24 of bupropion and about the same AUC.sub.0-24 of dextromethorphan in a human being as administering: about 210 mg of bupropion hydrochloride and about 90 mg of dextromethorphan hydrobromide to the human being. 13. The dosage form of claim 12, comprising about 210 mg of bupropion hydrochloride and about 90 mg of dextromethorphan hydrobromide. 14. The dosage form of claim 12, wherein the dextromethorphan is formulated for immediate release. 15. The dosage form of claim 12, wherein the bupropion is formulated for sustained release. 16. A method of systemically delivering bupropion and dextromethorphan, comprising administering the dosage form of claim 12 to a human being. 17. The method of claim 16, wherein the dosage form is administered orally. 18. The method of claim 16, wherein the dosage form is administered once daily. 19. The method of claim 16, wherein the dosage form is administered for at least 8 consecutive days. 20. The method of claim 16, wherein the dosage form is administered for at least 14 consecutive days. 21. The method of claim 16, wherein the dosage form is administered for at least 30 consecutive days.